Trovagene Inc. (NASDAQ:TROV) saw an uptick in trading volume on Tuesday . 377,549 shares changed hands during trading, an increase of 17% from the previous session’s volume of 321,646 shares.The stock last traded at $5.19 and had previously closed at $4.86.

A number of brokerages recently commented on TROV. Piper Jaffray Cos. reaffirmed a “hold” rating and set a $5.00 price objective (down from $8.00) on shares of Trovagene in a research report on Thursday, May 12th. Leerink Swann reiterated a “hold” rating on shares of Trovagene in a research note on Thursday, May 12th. Argus cut shares of Trovagene from a “buy” rating to a “hold” rating in a research note on Thursday, April 28th. Maxim Group reiterated a “buy” rating on shares of Trovagene in a research note on Monday, June 6th. Finally, Cantor Fitzgerald reiterated a “buy” rating and issued a $10.00 target price on shares of Trovagene in a research note on Monday, March 28th. Six analysts have rated the stock with a hold rating and three have given a buy rating to the company. Trovagene currently has an average rating of “Hold” and an average price target of $6.96.

The firm has a 50 day moving average price of $4.81 and a 200 day moving average price of $4.78. The stock’s market capitalization is $151.69 million.

Trovagene (NASDAQ:TROV) last posted its earnings results on Tuesday, May 10th. The company reported ($0.36) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.29) by $0.07. On average, equities analysts anticipate that Trovagene Inc. will post ($1.30) EPS for the current fiscal year.

Trovagene, Inc (TrovaGene) is a molecular diagnostic company. The Company focuses on the development and commercialization of a molecular diagnostic technology for use in disease detection and monitoring across a range of medical disciplines. Its primary internal focus is to leverage its cell-free molecular diagnostic platform to facilitate improvements in the field of oncology, while its external focus includes entering into license agreements or collaborations to develop its technology in areas, such as infectious disease, transplant medicine and prenatal genetics.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.